Merck's Keytruda: A Remarkable Science-To-Success Story
This article was originally published in Scrip
Executive Summary
With the probability of a drug making it from discovery to FDA approval extremely low – with some estimates putting the success rate at only one in every 5,000 – the story of how Merck's checkpoint inhibitor Keytruda (pembrolizumab) came to the marketplace is nothing short of remarkable.